Table 2.
Treatment 1 | |||||||||
---|---|---|---|---|---|---|---|---|---|
Mestizos | Seris | Yaquis | |||||||
Variables | Baseline m (IQR) | AT m (IQR) | p -value | Baseline m (IQR) | AT m (IQR) | p-value | Baseline m (IQR) | AT m (IQR) | p-value |
BMI (km/m2) | 16.8 (15.2, 19.8) | 16.7 (15.2, 20.0) | 0.94 | 17.6 (15.5, 20.5) | 17.7 (15.4, 22.0) | 0.84 | 16.1 (14.7, 18.7) | 17.1 (15.5, 19.5) | 9.0 × 10− 3 |
BMI z-score | 0.3 (−0.4,1.8) | 0.2(−0.5,1.1) | 0.03 | −0.4(− 0.8,0.6) | −0.5(− 0.8,0.3) | 0.85 | −0.4(− 0.8,0.1) | −0.4(− 0.7,0.4) | 0.63 |
TC (mg/dl) | 163.5 (141.5, 193.8) | 162.5 (137.5, 179.7) | 0.11 | 154.5 (134.5, 170.0) | 134.4 (116.9, 150.2) | 2.0 × 10− 4 | 147.0 (133.0, 162.0) | 139.2 (118.8, 153.6) | 1.0 × 10− 4 |
LDL (mg/dl) | 76.1 (65.2, 96.6) | 101.6 (83.1, 118.3) | 1.0 × 10− 4 | 73.2 (64.0, 82.1) | 94.1 (80.2, 106.5) | 1.0 × 10− 4 | 75.0 (66.0, 83.5) | 81.2 (66.8, 98.0) | 9.0 × 10− 3 |
HDL (mg/dl) | 61.0 (55.6, 68.3) | 56.6 (51.7, 66.2) | 0.23 | 53.7 (50.4, 59.2) | 53.4 (47.7, 59.0) | 0.16 | 55.0 (48.4, 59.8) | 46.3 (40.3, 53.2) | 1.0 × 10− 4 |
TGL (mg/dl) | 91.0 (67.8, 131.8) | 55.0 (40.8, 71.8) | 1.0 × 10− 4 | 77.0 (61.0,103.5) | 60.0 (43.0, 83.1) | 6.0 × 10− 3 | 83.0 (59.0, 108.0) | 60.0 (46.2, 83.6) | 1.0 × 10− 4 |
GL (mg/dl) | 89.9 (85.3, 93.3) | 84.4 (79.8, 88.4) | 4.0 × 10−4 | 80.0 (73.3, 84.0) | 93.6 (88.2, 98.5) | 1.0 × 10− 4 | 90.0 (86.0, 95.0) | 84.9 (78.5, 89.8) | 1.0 × 10− 4 |
Hb1AC (%) | 5.4 (5.5,5.7) | 5.4 (5.2, 5.7) | 0.45 | 5.6 (5.5,5.7) | 5.8 (5.6, 6.0) | 1.0 × 10−3 | 5.5 (5.4, 5.6) | 5.5 (5.2, 5.8) | 0.38 |
involvement